Vera Therapeutics/$VERA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Ticker
$VERA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
152
ISIN
US92337R1014
Website
VERA Metrics
BasicAdvanced
$1.4B
-
-$3.00
1.13
-
Price and volume
Market cap
$1.4B
Beta
1.13
52-week high
$49.23
52-week low
$18.53
Average daily volume
2.4M
Financial strength
Current ratio
27.682
Quick ratio
26.94
Long term debt to equity
9.958
Total debt to equity
10.18
Interest coverage (TTM)
-25.73%
Profitability
EBITDA (TTM)
-193.073
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-23.46%
Return on equity (TTM)
-39.49%
Valuation
Price to book
2.7
Price to tangible book (TTM)
2.7
Price to free cash flow (TTM)
-8.471
Free cash flow yield (TTM)
-11.80%
Free cash flow per share (TTM)
-267.37%
Growth
Earnings per share change (TTM)
46.40%
3-year earnings per share growth (CAGR)
8.95%
What the Analysts think about VERA
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
Bulls say / Bears say
Vera Therapeutics received Breakthrough Therapy Designation from the FDA for atacicept in treating IgA Nephropathy, potentially accelerating its development and approval process. (globenewswire.com)
The company expanded its atacicept development program to include multiple autoimmune kidney diseases, broadening its market potential. (globenewswire.com)
Analysts have set a consensus price target of $63.50 for Vera Therapeutics, indicating significant upside from current levels. (etfdailynews.com)
Vera Therapeutics' stock hit a 52-week low of $31.64 on February 14, 2025, reflecting investor concerns over its valuation. (investing.com)
The company announced a $200 million share offering on January 29, 2024, leading to a 4.7% premarket decline, which may indicate potential dilution concerns among investors. (tradingview.com)
CEO Marshall Fordyce sold 23,125 shares on September 25, 2024, at an average price of $46.05, which could be perceived negatively by investors. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
VERA Financial Performance
Revenues and expenses
VERA Earnings Performance
Company profitability
VERA News
AllArticlesVideos
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
MarketBeat·3 weeks ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vera Therapeutics stock?
Vera Therapeutics (VERA) has a market cap of $1.4B as of June 30, 2025.
What is the P/E ratio for Vera Therapeutics stock?
The price to earnings (P/E) ratio for Vera Therapeutics (VERA) stock is 0 as of June 30, 2025.
Does Vera Therapeutics stock pay dividends?
No, Vera Therapeutics (VERA) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Vera Therapeutics dividend payment date?
Vera Therapeutics (VERA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vera Therapeutics?
Vera Therapeutics (VERA) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.